The pharmaceutical industry is entering one of the most consequential periods in its history. Between 2025 and 2030, over $300 billion in annual prescription drug revenue is projected to lose patent protection — a wave of expiries roughly three times larger than the previous patent cliff seen around 2016. For pharmaceutical executives, the question is no longer whether their organisation will be affected, but how prepared they are to respond.
The Scale of the Challenge
Nearly 200 drugs will lose patent exclusivity during this window, including approximately 70 blockbusters — each generating over $1 billion in annual sales. The pressure is not evenly distributed. Bristol Myers Squibb faces roughly 47% of its revenues at risk by 2030, driven primarily by the forthcoming expiries of Eliquis and Opdivo. Merck has approximately 56% of its revenue concentrated in Keytruda alone, the best-selling cancer immunotherapy in the world, with peak sales expected around 2026 before biosimilar competition begins to erode the market. Pfizer faces approximately 33% revenue exposure from Prevnar, Ibrance, and Xtandi.
Not every company is in the same position. Eli Lilly, buoyed by massive GLP-1 revenues, faces limited patent exposure and has strengthened its pipeline to a degree that revenue is projected to improve significantly through 2030. The divergence in outcomes between companies will largely reflect the quality of strategic decisions made in the next 12 to 24 months.
What History Tells Us
The previous patent cliff, approximately a decade ago, eroded around $100 billion in brand-name sales. The current one is three times that size. What history also shows is that post-exclusivity revenue erosion can be steep and swift — branded revenues can collapse by 80% or more within 12 to 18 months of generic or biosimilar entry. Pfizer's Lipitor experienced a 71% sales decline within one year of patent expiry. Humira's revenue fell from over $21 billion in 2022 to around $9 billion in 2024 after losing exclusivity — though AbbVie's management of that transition has since become a widely studied case in portfolio resilience.
"AbbVie's strategy illustrates one viable path: patient sequencing of biosimilar competition through settlement agreements, simultaneous investment in next-generation assets (Rinvoq and Skyrizi), and targeted M&A."
The company reduced its dependence on Humira from 39% of revenues in 2022 to a projected 9% in 2025, while next-generation products rose from 14% to 43% over the same period.
Four Strategic Responses Executive Teams Are Prioritising
1. Reformulation and lifecycle management
Reformulation has emerged as the highest-ROI short-term response. By shifting patients to a new delivery route — for example, from intravenous to subcutaneous administration — companies can generate fresh intellectual property with new exclusivity windows. Merck's development of Keytruda Qlex (a subcutaneous reformulation of pembrolizumab) is the most prominent current example, with analysts projecting potential sales of $7 billion by the early 2030s. Reformulation programs can typically be completed in two to three years, compared to 10 to 15 years for entirely new molecular entities.
2. Accelerated M&A and pipeline acquisition
Total pharma M&A deal value reached $240 billion in 2025, representing an 81% year-over-year increase and the strongest M&A activity since 2019. Projections for 2026 point to nearly 520 deals totalling over $230 billion. However, M&A alone cannot close a $300 billion gap. Most acquisitions involve pre-revenue or early-revenue assets that require years of development before generating meaningful returns. Executive teams that rely exclusively on deal-making are likely to face a painful mid-decade revenue valley.
3. Therapeutic area diversification and indication expansion
Companies heavily concentrated in one therapy area face disproportionate cliff risk. Portfolio repositioning — moving into oncology adjacencies, rare diseases, or high-growth areas such as obesity and cardiometabolic disease — is a medium-term strategy that requires pipeline investment today to pay off post-cliff.
4. Biosimilar development as an opportunity
For companies with strong biologics manufacturing capability, the loss of exclusivity on competitors' drugs represents a commercial opportunity. The biosimilars market is expanding, and companies with the manufacturing infrastructure and regulatory experience to develop and launch biosimilars can offset branded revenue losses with contract manufacturing revenue and biosimilar sales.
The Leadership Imperative
What separates companies that emerge from patent cliffs stronger is not a single strategy but the quality of the organisational response — the ability to anticipate, restructure, and execute across multiple workstreams simultaneously. The companies that fared best in previous cliff cycles moved earlier, diversified more deliberately, and maintained greater visibility into the forward revenue pipeline.
For pharma CEOs, CFOs, and heads of R&D, the patent cliff of 2025 to 2030 is not an abstract future risk. It is the defining strategic challenge of the current decade. The conversations happening in boardrooms right now — about pipeline investment, deal thresholds, business model innovation, and commercial model restructuring — will determine which companies thrive and which face existential revenue gaps.